(ALLO) Allogene Therapeutics - Overview
Stock: UCART19, Cemacabtagene, ALLO-501, ALLO-316, ALLO-329
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.7% |
| Relative Tail Risk | -9.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.49 |
| Alpha | -15.73 |
| Character TTM | |
|---|---|
| Beta | 1.271 |
| Beta Downside | 1.464 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.82% |
| CAGR/Max DD | -0.43 |
Description: ALLO Allogene Therapeutics December 31, 2025
Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage immuno-oncology firm that engineers “off-the-shelf” allogeneic CAR-T cell products for cancer and autoimmune indications. Its lead candidates include UCART19 for relapsed/refractory CD19⁺ B-cell acute lymphoblastic leukemia and cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, alongside a pipeline of other allogeneic CAR-T programs targeting DLL3, Claudin-18.2, and FLT3.
Key operating metrics (as of Q3 2024) show a cash runway of roughly 12 months, with quarterly R&D spend averaging $120 million and a net loss of $210 million, reflecting the high capital intensity of CAR-T development. The allogeneic CAR-T market is projected to grow at a CAGR of ~30 % through 2030, driven by lower manufacturing costs and faster patient access compared with autologous therapies-a sector trend that directly benefits Allogene’s business model.
Strategic collaborations with Pfizer, Servier, Cellectis, and MD Anderson provide both funding (e.g., a $200 million upfront payment from Pfizer) and validation of the platform, while the partnership with Foresight Diagnostics to create an MRD-based assay could create a companion-diagnostic revenue stream.
For a deeper, data-driven assessment of ALLO’s valuation assumptions and risk profile, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -212.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 0.84 > 1.0 |
| NWC/Revenue: 1.04m% < 20% (prev 286.2k%; Δ 754.2k% < -1%) |
| CFO/TA -0.36 > 3% & CFO -158.3m > Net Income -212.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (222.0m) vs 12m ago 6.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.00% > 50% (prev 0.02%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: -250.0 > 6 (EBITDA TTM -198.2m / Interest Expense TTM 843.0k) |
Altman Z'' -15.00
| A: 0.52 (Total Current Assets 260.7m - Total Current Liabilities 31.8m) / Total Assets 439.8m |
| B: -4.48 (Retained Earnings -1.97b / Total Assets 439.8m) |
| C: -0.41 (EBIT TTM -210.7m / Avg Total Assets 514.4m) |
| D: -15.84 (Book Value of Equity -1.97b / Total Liabilities 124.4m) |
| Altman-Z'' Score: -30.59 = D |
Beneish M -2.12
| DSRI: 3.24 (Receivables 2.10m/2.80m, Revenue 22.0k/95.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.56 (AQ_t 0.14 / AQ_t-1 0.25) |
| SGI: 0.23 (Revenue 22.0k / 95.0k) |
| TATA: -0.12 (NI -212.0m - CFO -158.3m) / TA 439.8m) |
| Beneish M-Score: -2.12 (Cap -4..+1) = BB |
What is the price of ALLO shares?
Over the past week, the price has changed by -8.15%, over one month by +19.86%, over three months by +60.95% and over the past year by +5.62%.
Is ALLO a buy, sell or hold?
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALLO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.4 | 336.7% |
| Analysts Target Price | 7.4 | 336.7% |
| ValueRay Target Price | 1.4 | -17.8% |
ALLO Fundamental Data Overview February 03, 2026
P/B = 1.3113
Revenue TTM = 22.0k USD
EBIT TTM = -210.7m USD
EBITDA TTM = -198.2m USD
Long Term Debt = 77.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.01m USD (from shortTermDebt, last quarter)
Debt = 85.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 47.3m USD (from netDebt column, last quarter)
Enterprise Value = 246.5m USD (413.5m + Debt 85.1m - CCE 252.2m)
Interest Coverage Ratio = -250.0 (Ebit TTM -210.7m / Interest Expense TTM 843.0k)
EV/FCF = -1.55x (Enterprise Value 246.5m / FCF TTM -159.0m)
FCF Yield = -64.51% (FCF TTM -159.0m / Enterprise Value 246.5m)
FCF Margin = -722.7k% (FCF TTM -159.0m / Revenue TTM 22.0k)
Net Margin = -963.7k% (Net Income TTM -212.0m / Revenue TTM 22.0k)
Gross Margin = unknown ((Revenue TTM 22.0k - Cost of Revenue TTM 40.6m) / Revenue TTM)
Tobins Q-Ratio = 0.56 (Enterprise Value 246.5m / Total Assets 439.8m)
Interest Expense / Debt = 0.40% (Interest Expense 344.0k / Debt 85.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -166.5m (EBIT -210.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.19 (Total Current Assets 260.7m / Total Current Liabilities 31.8m)
Debt / Equity = 0.27 (Debt 85.1m / totalStockholderEquity, last quarter 315.3m)
Debt / EBITDA = -0.24 (negative EBITDA) (Net Debt 47.3m / EBITDA -198.2m)
Debt / FCF = -0.30 (negative FCF - burning cash) (Net Debt 47.3m / FCF TTM -159.0m)
Total Stockholder Equity = 366.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.21% (Net Income -212.0m / Total Assets 439.8m)
RoE = -57.79% (Net Income TTM -212.0m / Total Stockholder Equity 366.9m)
RoCE = -47.46% (EBIT -210.7m / Capital Employed (Equity 366.9m + L.T.Debt 77.1m))
RoIC = -45.38% (negative operating profit) (NOPAT -166.5m / Invested Capital 366.9m)
WACC = 8.84% (E(413.5m)/V(498.6m) * Re(10.60%) + D(85.1m)/V(498.6m) * Rd(0.40%) * (1-Tc(0.21)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.85%
Fair Price DCF = unknown (Cash Flow -159.0m)
EPS Correlation: 91.12 | EPS CAGR: 49.83% | SUE: 4.0 | # QB: 1
Revenue Correlation: -77.77 | Revenue CAGR: -17.99% | SUE: -0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.21 | Chg30d=+0.007 | Revisions Net=+3 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.89 | Chg30d=+0.026 | Revisions Net=+1 | Growth EPS=+2.5% | Growth Revenue=+799.4%